PAA 2.94% 16.5¢ pharmaust limited

FDA Application for Orphan Drug Designation , PAA, MPL, page-340

  1. 2,584 Posts.
    lightbulb Created with Sketch. 1497
    Hi Theoc,
    I suspect the end of 2024 may be a bit early, the paperwork may be in and the approval process underway but actually getting it out there for sale over the counter may take a bit longer. I'm hoping it will not be Pharmausts problem anymore, or is that too much to hope for.

    Canine and MND both should be approved for use by 2027, I would say at a guess. 2027 is just the year several drugs sold by those companies, have patents expiring. I'm sure all big companies may be in a similar situation give or take a year.

    They are the only 3 I have looked at for the moment, and I just chose them at random. Other companies may well be a better fit for Monepantel. Most of the big companies appear to have large cash reserves at the moment to spend on M&A if they can find something worthwhile.

    The good part is we are now discussing commercialization not weather or not Monepantel may work, or wheter it will have adverse side effects etc.


    Cheers
 
watchlist Created with Sketch. Add PAA (ASX) to my watchlist
(20min delay)
Last
16.5¢
Change
-0.005(2.94%)
Mkt cap ! $80.22M
Open High Low Value Volume
17.0¢ 18.0¢ 16.5¢ $210.6K 1.236M

Buyers (Bids)

No. Vol. Price($)
2 274938 16.5¢
 

Sellers (Offers)

Price($) Vol. No.
17.0¢ 15000 2
View Market Depth
Last trade - 16.10pm 15/08/2024 (20 minute delay) ?
PAA (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.